Cancer Incidence and Mortality in Patients with Type 2 Diabetes Treated with Human Insulin: A Cohort Study in Shanghai
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
AIM: The aim was to investigate the association between human insulin and cancer incidence and mortality in Chinese patients with type 2 diabetes. METHODS: We recruited 8,774 insulin-naïve diabetes patients from the Shanghai Diabetes Registry (SDR). The follow-up rate was 85.4%. All subjects were divided into the insulin use cohort (n = 3,639) and the non-insulin use cohort (n = 5,135). The primary outcome was the first diagnosis of any cancer. The secondary outcome was all-cause mortality. Cox proportional hazards model was used to estimate the relative risk (RR) of cancer and mortality. RESULTS: We observed 98 cancer events in the insulin use cohort and 170 in the non-insulin use cohort. Cancer incidence rates were 78.6 and 74.3 per 10,000 patients per year in the insulin users and the non-insulin users, respectively. No significant difference in cancer risk was observed between the two cohorts (adjusted RR = 1.20, 95% CI 0.89-1.62, P = 0.228). Regarding site-specific cancers, only the risk of liver cancer was significantly higher in the insulin users compared to that in the non-insulin users (adjusted RR = 2.84, 95% CI 1.12-7.17, P = 0.028). The risks of overall mortality (adjusted RR = 1.89, 95% CI 1.47-2.43, P<0.0001) and death from cancer (adjusted RR = 2.16, 95% CI 1.39-3.35, P = 0.001) were all significantly higher in the insulin users than in the non-insulin users. CONCLUSION: There was no excess risk of overall cancer in patients with type 2 diabetes who were treated with human insulin. However, a significantly higher risk of liver cancer was found in these patients. Moreover, insulin users showed higher risks of overall and cancer mortality. Considering that individuals treated with insulin were more likely to be advanced diabetic patients, caution should be used in interpreting these results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
The Emerging Risk Factors Collaboration (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008862 · Cited by 2,726 · cited 1×
“3) The HbA1c levels were higher in the insulin use cohort at both baseline and endpoint than in the noninsulin use cohort, and high glucose levels may accelerate tumor progression [21] and death [22].”
BackgroundGiovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366
Basal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636 · cited 2×
“The result is consistent with the ORIGIN trial [12] which reported that insulin glargine had a neutral effect on cancers.”
Vigneri, P., Frasca, F., Sciacca, L., Pandini, G., & Vigneri, R. (2009) · Endocrine Related Cancer · doi:10.1677/erc-09-0087 · Cited by 1,009
Bowker, S. L., Majumdar, S. R., Veugelers, P., & Johnson, J. A. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1558 · Cited by 933
Hemkens, L. G., Grouven, U., Bender, R., Günster, C., Gutschmidt, S., Selke, G. W., & Sawicki, P. T. (2009) · Diabetologia · doi:10.1007/s00125-009-1418-4 · Cited by 607 · cited 1×
“Some results showed that insulin was associated with an increased cancer risk [3], [4], [5], [6], [7], while others suggested that insulin did not play a role in cancer development [8].”
BackgroundJonasson, J. M., Ljung, R., Talbäck, M., Haglund, B., Gudbjörnsdòttir, S., & Steineck, G. (2009) · Diabetologia · doi:10.1007/s00125-009-1444-2 · Cited by 412
Rosenstock, J., Fonseca, V., McGill, J. B., Riddle, M., Hallé, J. P., Hramiak, I., Johnston, P., & Davis, M. (2009) · Diabetologia · doi:10.1007/s00125-009-1452-2 · Cited by 141
Cited by
Jones, S. E., Lane, J. M., Wood, A. R., van Hees, V. T., Tyrrell, J., Beaumont, R. N., Jeffries, A. R., Dashti, H. S., Hillsdon, M., Ruth, K. S., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08259-7 · Cited by 691
Role of tau protein in Alzheimer’s disease: The prime pathological player
Muralidar, S., Ambi, S. V., Sekaran, S., Thirumalai, D., & Palaniappan, B. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.07.327 · Cited by 278
Evidence for DNA Damage as a Biological Link Between Diabetes and Cancer
Lee, S. C., & Chan, J. C. (2015) · Chinese Medical Journal · doi:10.4103/0366-6999.157693 · Cited by 106
“controversial, as some epidemiological studies do not show a correlation between use of insulin and all‐site cancer[6]”
BackgroundWhitehouse, L. N. A., & Lapointe, B. E. (2015) · Journal of Experimental Marine Biology and Ecology · doi:10.1016/j.jembe.2015.06.012 · Cited by 30
Metadata
- Authors
- Gu, Y., Wang, C., Zheng, Y., Hou, X., Mo, Y., Yu, W., Zhang, L., Hu, C., Nan, H., Chen, L., Li, J., Liu, Y., Huang, Z., Han, M., Bao, Y., Zhong, W., & Jia, W.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-01-07
- Volume
- 8
- Issue
- 1
- Pages
- e53411
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2052225121
- Cited by
- 55
- References
- 8
- FWCI
- 3.50
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cancer Incidence and Mortality in Patients with Type 2 Diabetes Treated with Human Insulin: A Cohort Study in Shanghai. https://app.cochat.ai/papers/10.1371/journal.pone.0053411
- The paper
- Gu, Y., Wang, C., Zheng, Y., Hou, X., Mo, Y., Yu, W., Zhang, L., Hu, C., Nan, H., Chen, L., Li, J., Liu, Y., Huang, Z., Han, M., Bao, Y., Zhong, W., & Jia, W. (2013). Cancer Incidence and Mortality in Patients with Type 2 Diabetes Treated with Human Insulin: A Cohort Study in Shanghai. PLoS ONE. https://doi.org/10.1371/journal.pone.0053411
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.